Develops RNA-activation and siRNA medicines. Representative programs include RAG-01 for NMIBC, RAG-18 for DMD and RAG-17 for SOD1-associated ALS. Stages are tied to dated issuer disclosures; this is not a complete pipeline or independent efficacy validation.
Profile review: 2026-11-07 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Founded in 2017; the company lists Suzhou headquarters, Rudong manufacturing and a Shanghai business office.
RNAa uses small activating RNA; saRNA here does not mean self-amplifying mRNA.
Company describes a safety run-in and cohorts studying monotherapy and combination with mitomycin C. Site initiation does not establish enrollment completion or efficacy.
Issuer cites NCT07282652, not independently checked here. The open-label cohort comprised three participants through Day 169. NSAA declined by three points in all three; six-minute walk results were mixed. Target-protein changes do not establish clinical benefit.
Program / service
Target / indication
Representative stage
Evidence & scope
RAG-17
SOD1 · SOD1-associated ALS
Phase 1/2；2026-04-21Company announcement称II期给药中
Investigational human study
RAG-01
CDKN1A / p21 · Intermediate- or high-risk non-muscle-invasive bladder cancer
Phase 2；2026-11-02公司披露中国RAG010201研究启动
Investigational human study
RAG-18
UTRN / utrophin · Duchenne muscular dystrophy
Phase 1；2026-10-03公司披露首个人体剂量递增研究
Investigational human study
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
On November 2, Ractigen Therapeutics announced initiation of RAG010201, led by Fudan University Shanghai Cancer Center. The China Phase 2 study evaluates intravesical RAG-01 alone and with mitomycin C in intermediate- or high-risk non-muscle-invasive bladder cancer, using a safety run-in and separate cohorts. Site initiation does not establish enrollment completion or efficacy.
Phio announced a November 7 SITC oral presentation of final Phase 1b findings for intratumoral PH-762, its PD-1-silencing siRNA candidate, in cutaneous carcinomas. The company described tolerability and potential tissue-sparing neoadjuvant use, while stating that additional safety and efficacy studies are needed. A Phase 2b study is planned for the first half of 2027.
Vir Biotechnology announced that Phase 3 ECLIPSE 1 results for elebsiran plus tobevibart in chronic hepatitis delta will be presented on November 8, with an investor discussion on November 9. Elebsiran is an HBV-targeting siRNA; tobevibart is an antibody. The release announces the forthcoming readout and expanded Phase 2 presentations but does not disclose the Phase 3 numerical results.
A Nature Communications study reports a peptide–oligonucleotide nanohybrid for bone-targeted miR-26a-5p delivery. The original abstract describes reduced GSK-3β expression and stabilization of HIF-1α, supporting coupled bone formation and angiogenesis. Systemic administration limited skeletal and vascular injury in a rat glucocorticoid-induced bone-loss model. This is preclinical miRNA delivery, not oral cyclic peptide therapy or human efficacy evidence.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Pipeline and dated release differ; registry status and clinical efficacy were not independently established. Logo and latest financing round remain unverified.
